Inhibitors of cyclin-dependent kinases as cancer therapeutics.

Whittaker, Steven R., Mallinger, Aurélie, Workman, Paul, Clarke, Paul A.·2017·Pharmacology & Therapeutics
DOI 10.1016/j.pharmthera.2017.02.008

Cited by (402)

Items 201–300 of 402

  1. Design, synthesis and biological assessment of novel CDK4 inhibitor with potent anticancer activity
    Yongtao Li, Renle Du, Yongwei Nie, Tianqi Wang, Yakun Ma, Yan Liang Fan · 2021 · Bioorganic Chemistry
  2. Cellular senescence and abdominal aortic aneurysm: From pathogenesis to therapeutics
    Ding Wang, Xinyu Hao, Longyuan Jia, Yuchen Jing, Bo Jiang, Shijie Xin · 2022 · Frontiers in Cardiovascular Medicine
  3. Discovery and optimization of thieno[3,2-d]pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7
    Hongjin Zhang, Guohao Lin, Suyun Jia, Ying Zhang, Jianbo Wu, Yanxin Tao, Weixue Huang, Meiru Song, Ke Ding, Dawei Ma et al. · 2023 · European Journal of Medicinal Chemistry
  4. Discovery of a class of diheteroaromatic amines as orally bioavailable CDK1/4/6 inhibitors
    Yan Fu, Shuai Tang, Yi‐Chang Su, Xiaojing Lan, Yan Ye, Chuantao Zha, Lei Li, Jianhua Cao, Yi Chen, Lei Jiang et al. · 2017 · Bioorganic & Medicinal Chemistry Letters
  5. Combination therapies for MPNSTs targeting RABL6A-RB1 signaling
    Jordan L. Kohlmeyer, David J. Gordon, Munir R. Tanas, Rebecca D. Dodd, Varun Monga, Benjamin W. Darbro, Dawn E. Quelle · 2021 · Oncotarget
  6. Structural basis of T-loop–independent recognition and activation of CDKs by the CDK-activating kinase
    Victoria I. Cushing, Amy J. S. McGeoch, Sophie L. Williams, Theodoros I. Roumeliotis, Junjie Feng, Lucy M. Dan, Jyoti Sharma Choudhary, Norman E. Davey, Basil J. Greber · 2025 · Science
  7. Role of specific CDKs in regulating DNA damage repair responses and replication stress
    Rahul Roy, Siri Chandana Gampa, Sireesha V. Garimella · 2024 · Current Opinion in Pharmacology
  8. Neuregulin-4, an Adipokine, as a Residual Risk Factor of Atherosclerotic Coronary Artery Disease
    Tatsuyuki Sato, Shun Minatsuki · 2019 · International Heart Journal
  9. Cyclin-Dependent Kinases As Potential Targets for Colorectal Cancer: Past, Present and Future
    Sonal M. Manohar · 2022 · Future Medicinal Chemistry
  10. Clinical Progress of Targeted Therapy for Breast Cancer: A Comprehensive Review
    Abhijit Debnath, Rupa Mazumder · 2024 · Current Cancer Drug Targets
  11. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors
    Gaomin Zhang, Yujie Ren · 2018 · Molecules
  12. Function, Structure and Topology of Protein Kinases
    Sandra Röhm, Andreas Krämer, Stefan Knapp · 2020 · Topics in medicinal chemistry
  13. Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER+HER2−Rb wild-type and knock-down in breast cancer cell lines
    Oliviero Marinelli, Emanuela Romagnoli, Federica Maggi, Massimo Nabissi, Consuelo Amantini, Maria Beatrice Morelli, Matteo Santoni, Nicola Battelli, Giorgio Santoni · 2020 · BMC Cancer
  14. An Interpretable Multitask Framework BiLAT Enables Accurate Prediction of Cyclin-Dependent Protein Kinase Inhibitors
    Qian Xu, Xiaowen Dai, Lin Luo, MingDe Lin, Yuan Xu, Yang Zhao, Dingfang Huang, Haodi Qiu, Li Liang, Haichun Liu et al. · 2023 · Journal of Chemical Information and Modeling
  15. Discovery of small molecule degraders for modulating cell cycle
    Liguo Wang, Zhouli Yang, Guangchen Li, Yongbo Liu, Chao Ai, Yu Rao · 2023 · Frontiers of Medicine
  16. Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs): bench to bedside
    Ali Hassanzadeh, Navid Shomali, Amin Kamrani, Mohammad Sadegh Soltani‐Zangbar, Hadi Nasiri, Morteza Akbari · 2024 · EXCLI journal
  17. Structure-Guided Discovery of Novel N4-(Substituted Thiazol-2-yl)-N2-(4-Substituted phenyl)pyrimidine-2,4-Diamines as Potent CDK2 and CDK9 Dual Inhibitors with High Oral Bioavailability
    Bei Zhang, Yanhong Li, Yukang Lin, Ting Wang, Lin Chen, Jianfan Cai, Tangyang Ji, Peng-Cheng Diao, Yufeng Ma, Yan-ting Yann Zhang et al. · 2025 · Journal of Medicinal Chemistry
  18. Discovery of potent and selective CDK2 inhibitors with high safety and favorable bioavailability for the treatment of cancer
    Weijiao Chen, Xujie Zhuang, Yuanyuan Chen, Linhu Shen, Huanaoyu Yang, Minjie Wang, Guoyong Pan, Jinke Tan, Xu Pan, Sikai Feng et al. · 2025 · European Journal of Medicinal Chemistry
  19. 5-Oxo-dihydropyranopyran derivatives as anti-proliferative agents; synthesis, biological evaluation, molecular docking, MD simulation, DFT, and in-silico pharmacokinetic studies
    Sara Ranjbar, Paria Sadeghian, Sara Khademian, Mina Emami, Zahra Pakrouh Jahromi, Seyedeh Habibeh Mirmajidi, Fatemeh Zare, Manica Negahdaripour, Younes Ghasemi, Mehdi Khoshneviszadeh · 2024 · Heliyon
  20. Discovery of Novel N-(5-(Pyridin-3-yl)-1H-indazol-3-yl)benzamide Derivatives as Potent Cyclin-Dependent Kinase 7 Inhibitors for the Treatment of Autosomal Dominant Polycystic Kidney Disease
    Bowen Yang, Haoran Zhang, Na Li, Lixin Gao, Hong Jiang, Weijuan Kan, Haoxing Yuan, Jia Xuan Li, Dongmei Zhao, Bing Xiong et al. · 2022 · Journal of Medicinal Chemistry
  21. Cell cycle progression mechanisms: slower cyclin-D/CDK4 activation and faster cyclin-E/CDK2
    Wengang Zhang, Yonglan Liu, Hyunbum Jang, Ruth Nussinov · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  22. A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020–present
    Xiaoling Huang, Shidi Xu, Lei Duan, Shan Xu, Wufu Zhu · 2024 · Expert Opinion on Therapeutic Patents
  23. Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment
    Weijiao Chen, Xujie Zhuang, Yuanyuan Chen, Huanaoyu Yang, Linhu Shen, Sikai Feng, Wenjian Min, Kai Yuan, Peng Yang · 2025 · Chinese Journal of Natural Medicines
  24. Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer
    Isabel Echavarría, Yolanda Jerez, Miguel Martín, Sara López‐Tarruella · 2017 · Breast Care
  25. Synthesis and Characterization of Plumbagin S-Allyl Cysteine Ester: Determination of Anticancer Activity In Silico and In Vitro
    Sudha Vijayan, Chitra Loganathan, Penislusshiyan Sakayanathan, Thayumanavan Palvannan · 2022 · Applied Biochemistry and Biotechnology
  26. A Perspective Study on the RTK, PI3K, B‐Raf, CDK and the Multi‐Protein Targeting in Medicinal Chemistry
    Abdalla R. Mohamed, Ahmed Mahmoud El Kerdawy · 2022 · Chemistry & Biodiversity
  27. miR-508-5p serves as an anti-oncogene by targeting S100A16 to regulate AKT signaling and epithelial-mesenchymal transition process in lung adenocarcinoma cells
    Chaohui Wu, Jiansheng Yang, Xianbin Lin, Rongbin Li, Jingyang Wu · 2023 · The American Journal of the Medical Sciences
  28. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions
    Mark Alan Klein · 2019 · Advances in protein chemistry and structural biology
  29. Novel 1,3,5‐triazine‐nicotinohydrazide derivatives induce cell arrest and apoptosis in osteosarcoma cancer cells and inhibit osteosarcoma in a patient‐derived orthotopic xenograft mouse model
    Qing Su, Baolin Xu, Zhoubin Tian, Ziling Gong · 2021 · Chemical Biology & Drug Design
  30. Discovery of 3-Amino-1H-pyrazole-Based Kinase Inhibitors to Illuminate the Understudied PCTAIRE Family
    Jennifer Alisa Amrhein, Lena M. Berger, Amelie Tjaden, Andreas Krämer, Lewis Elson, Tuomas Aleksi Tolvanen, Daniel Martinez Molina, Astrid Kaiser, Manfred Schubert‐Zsilavecz, Susanne Müller et al. · 2022 · International Journal of Molecular Sciences
  31. Protein kinases as therapeutic targets to develop anticancer drugs with natural alkaloids
    Hanlin Ye, Linlin Wang, Li Ma, Максим Йонов, Gan Qiao, Jianlin Huang, Cheng Li, Yuxi Zhang, Xiaohui Yang, Shousong Cao et al. · 2021 · Frontiers in Bioscience-Landmark
  32. CDK7 inhibition induces apoptosis in acute myeloid leukemia cells and exerts synergistic antileukemic effects with azacitidine in vitro and in vivo
    Shuai Zhang, Ru Feng, Jiefei Bai, Shangyong Ning, Xiaodong Xu, Jie Lena Sun, Meng Yin Wu, Hui Liu · 2023 · Leukemia & lymphoma/Leukemia and lymphoma
  33. Preparation and Evaluation of [18F]AlF-NOTA-PBB for PET Imaging of Cyclin-dependent Kinase 4/6 in Tumors
    Di Xiao, Qianqian Gan, Xiaojiang Duan, Qianna Wang, Yuhao Jiang, Peiwen Han, Junbo Zhang · 2023 · Molecular Pharmaceutics
  34. Discovery of novel macrocyclic derivatives as potent and selective cyclin-dependent kinase 2 inhibitors
    Pengpeng Niu, Yanxin Tao, Qingyuan Meng, Y.‐Z. HUANG, Shan Li, Ke Ding, Dawei Ma, Zu Ye, Mengyang Fan · 2024 · Bioorganic & Medicinal Chemistry
  35. Discovery of novel CDK4/6 inhibitors from fungal secondary metabolites
    Abhijit Debnath, Rupa Mazumder, Rajesh Kumar Singh, Anil Kumar Singh · 2024 · International Journal of Biological Macromolecules
  36. Radiosensitizing Effect of Novel Phenylpyrimidine Derivatives on Human Lung Cancer Cells via Cell Cycle Perturbation
    Seung-Youn Jung, Ky‐Youb Nam, Jeong‐In Park, Kyung‐Hee Song, Jiyeon Ahn, Jong Kuk Park, Hong‐Duck Um, Sang‐Gu Hwang, Sang Un Choi, Jie‐Young Song · 2019 · Journal of Pharmacology and Experimental Therapeutics
  37. Expression and prognostic value of transcription-associated cyclin-dependent kinases in human breast cancer
    Ning Li, Shaoquan Zheng, Zhicheng Xue, Zhenchong Xiong, Yutian Zou, Yuhui Tang, Weidong Wei, Lu Yang · 2021 · Aging
  38. Discovery of novel inhibitors of CDK2 using docking and physics‐based binding free energy calculation
    Lei Zheng, Yunpeng Yang, Jingxiao Bao, Liping He, Yifei Qi, John Z. H. Zhang · 2022 · Chemical Biology & Drug Design
  39. Nuclear focal adhesion kinase induces APC/C activator protein CDH1-mediated cyclin-dependent kinase 4/6 degradation and inhibits melanoma proliferation
    James M. Murphy, Kyuho Jeong, Eun-Young Erin Ahn, Ssang‐Taek Lim · 2022 · Journal of Biological Chemistry
  40. Nano-Zirconium Dioxide Catalyzed Multicomponent Synthesis of Bioactive Pyranopyrazoles That Target Cyclin Dependent Kinase 1 in Human Breast Cancer Cells
    Basappa Basappa, Lisha K. Poonacha, Xi Zhang, Divakar Vishwanath, Ji-Rui Yang, Omantheswara Nagaraja, Ananda Swamynayaka, Madegowda Mahendra, Arunachalam Chinnathambi, Sulaiman Ali Alharbi et al. · 2023 · Biomedicines
  41. Insights into the selectivity of a brain-penetrant CDK4/6 vs CDK1/2 inhibitor for glioblastoma used in multiple replica molecular dynamics simulations
    Jiahao Sun, Shanshan Liang, Xinguo Liu, Shaolong Zhang, Meng Li, Qinggang Zhang, Jianzhong Chen · 2023 · Journal of Biomolecular Structure and Dynamics
  42. The role of cell cycle-related genes in the tumorigenesis of adrenal and thyroid neuroendocrine tumors
    Екатерина Сергеевна Просандеева, Ekaterina Gorodkova, Anastasia S. Shcherbakova, Walaa Asaad, Sergey Valentinovich Popov, Galina Afanas'evna Mel'nichenko, Natalya G. Mokrysheva, Marina V. Utkina · 2024 · Heliyon
  43. Emerging Mechanisms of Therapy Resistance in Metastatic ER+ Breast Cancer
    Thu Ha Truong, Natasha Ivelisse Roman Ortiz, Chinasa A Ufondu, Su‐Jeong Lee, Julie Hanson Ostrander · 2025 · Endocrinology
  44. DeepDegradome: A structure-aware deep learning framework for PROTAC and ligand generation against protein targets
    Qiaoyu Hu, Yu Cao, Pengxuan Ren, Xianglei Zhang, Fenglei Li, Xueyuan Zhang, Fengyu Cai, Ran Zhang, Yongqi Zhou, Lianghe Mei et al. · 2026 · Proceedings of the National Academy of Sciences
  45. Structural and binding studies of cyclin‐dependent kinase 2 with NU6140 inhibitor
    Sumalatha Rani Talapati, Megha Goyal, Vijayashankar Nataraj, Manoj Kumar Pothuganti, Sreevidya M.R., Suraj T. Gore, Murali Ramachandra, Thomas Antony, Sunil S. More, Narasimha K. Rao · 2021 · Chemical Biology & Drug Design
  46. Targeting cyclin-dependent kinases in sarcoma treatment: Current perspectives and future directions
    Alessandra Merlini, Valeria Pavese, Giulia Manessi, Martina Rabino, Francesco Tolomeo, Sandra Aliberti, Lorenzo D’Ambrosio, Giovanni Grignani · 2023 · Frontiers in Oncology
  47. New pyrrolidine‐carboxamide derivatives as dual antiproliferative EGFR / CDK2 inhibitors
    Frias Obaid Arhema Frejat, Bing Zhao, Nooruldeen Furaijit, Lihong Wang, Hesham A. Abou‐Zied, Hazem M. Fathy, Fatma A. Mohamed, Bahaa G. M. Youssif, Chunli Wu · 2023 · Chemical Biology & Drug Design
  48. Identification of Novel CDK 4/6 Inhibitors by High-throughput Virtual Screening
    Abhijit Debnath, Rupa Mazumder · 2024 · Letters in Drug Design & Discovery
  49. Molecules Inducing Specific Cyclin-Dependent Kinase Degradation and their Possible Use in Cancer Therapy
    Mingming Zheng, Xiaoyu Zhang, Weijiao Chen, Fei Xia, Huanaoyu Yang, Kai Yuan, Peng Yang · 2024 · Future Medicinal Chemistry
  50. Uncovering potential CDK9 inhibitors from natural compound databases through docking-based virtual screening and MD simulations
    Pooja Singh, Vikas Kumar, Tae Sung Jung, Jeong Sang Lee, Keun Woo Lee, Jong Chan Hong · 2024 · Journal of Molecular Modeling
  51. Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors
    Antonio Pannuti, Aleksandra Filipović, Chindo Hicks, Elliot J. Lefkowitz, Travis Ptacek, Justin Stebbing, Lucio Miele · 2018 · PLoS ONE
  52. Comparison of the Inhibitory Binding Modes Between the Planar Fascaplysin and Its Nonplanar Tetrahydro-β-carboline Analogs in CDK4
    Yan Liang, Huili Quan, Tong Bu, Xuedong Li, Xingang Liu, Songsong Wang, Dian He, Qingzhong Jia, Yang Zhang · 2021 · Frontiers in Chemistry
  53. Targeting the senescent surfaceome through DPP4 antibody-functionalized nanoparticles. An application to cancer therapy
    Blanca Escriche‐Navarro, Eva Garrido, Andrea Combalia Escudero, Isabel Montoya-Méndez, Félix Sancenón, Alba García‐Fernández, Ramón Martínez‐Máñez · 2025 · Biomaterials
  54. Imidazole-4-N-acetamide Derivatives as a Novel Scaffold for Selective Targeting of Cyclin Dependent Kinases
    Polina V. Rusina, Erik R. Gandalipov, Yana Abdusheva, Maria V. Panova, Alexandra Burdenkova, Vasiliy A. Chaliy, Maria Brachs, Oleg V. Stroganov, Ksenia Guzeeva, Igor V. Svitanko et al. · 2023 · Cancers
  55. Transient gene expression using valproic acid in combination with co‐transfection of SV40 large T antigen and human p21 CIP /p27 KIP
    Petra Kiszel, Sonja Fiesel, Susanne Voit, Beate Waechtler, Thomas Meier, Tobias Oelschlaegel, Michael Schräml, Alfred Michael Engel · 2019 · Biotechnology Progress
  56. Phenotypic Characterization of Targeted Knockdown of Cyclin-Dependent Kinases in the Intestinal Epithelial Cells
    Shuyan Lu, Tae Sung, Marina Amaro, Brad P. Hirakawa, Bart A. Jessen, Wenyue Hu · 2020 · Toxicological Sciences
  57. Extracts of edible, medicinal Thai plants inhibit the human breast cancer cells
    Benjaporn Buranrat, Ampa Konsue, Pornpimon Wongsuwan · 2020 · Tropical Journal of Pharmaceutical Research
  58. A Crosstalk Between Dual-Specific Phosphatases and Dual-Specific Protein Kinases Can Be A Potential Therapeutic Target for Anti-cancer Therapy
    Başak Çeltikçi · 2021 · Advances in experimental medicine and biology
  59. Direct Substrate Identification with an Analog Sensitive (AS) Viral Cyclin-Dependent Kinase (v-Cdk)
    Angie C. Umaña, Satoko Iwahori, Robert F. Kalejta · 2017 · ACS Chemical Biology
  60. Mediator Kinase Inhibitor Selectivity and Activity in Colorectal Cancer
    María Jesús Ortiz-Ruiz, Olajumoke Adeniji-Popoola, Konstantinos Mitsopoulos, Robert te Poele, Rahul S. Samant, Gary Box, Will Court, Alexis de Haven Brandon, Sharon M. Gowan, Aurélie Mallinger et al. · 2025 · ACS Chemical Biology
  61. Pan Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer
    Sepideh Izadi, Mohammad Hojjat‐Farsangi, Vahid Karpisheh, Farhad Jadidi‐Niaragh · 2023 · International Journal of Drug Research in Clinics
  62. Design, Molecular Docking, Synthesis, Characterization and Preliminary Evaluation of Novel 1,3,4-Oxadiazole Derivatives as Cyclin-Dependent Kinase 2 Inhibitors
    Yousef Sabah Ali, Monther Faisal Mahdi, Basma M. Abd Razik, Talal A. Aburjai · 2025 · Al Mustansiriyah Journal of Pharmaceutical Sciences
  63. Recent Trends in Rationally Designed Molecules as Kinase Inhibitors
    Parteek Prasher, Mousmee Sharma, Yinghan Chan, Sachin Kumar Singh, Krishnan Anand, Harish Dureja, Niraj Kumar Jha, Gaurav Gupta, Flavia C. M. Zacconi, Dinesh Kumar Chellappan et al. · 2021 · Current Medicinal Chemistry
  64. Potent inhibitors targeting cyclin-dependent kinase 9 discovered via virtual high-throughput screening and absolute binding free energy calculations
    Shipeng Wang, Fengjiao Liu, Pengfei Li, Jianing Wang, Yan Mo, Bin Lin, Ye Mei · 2024 · Physical Chemistry Chemical Physics
  65. Protein engineering enables a soakable crystal form of human CDK7 primed for high-throughput crystallography and structure-based drug design
    Manjeet Mukherjee, Philip J. Day, Duncan C. Laverty, Juan A. Bueren‐Calabuig, Andrew Woodhead, Charlotte Griffiths-Jones, Steve Hiscock, Charlotte East, Susan Boyd, Marc O’Reilly · 2024 · Structure
  66. Investigating the Effects of Chelidonic Acid on Oxidative Stress-Induced Premature Cellular Senescence in Human Skin Fibroblast Cells
    Burcu Türkoğlu, Banu Mansuroğlu · 2024 · Life
  67. Targeting cell cycle regulators: A new paradigm in cancer therapeutics
    Neelu Mishra, AASTHA SONI, MANSHI KUMARI, Garima Singh, Sonika Kumari Sharma, Samarendra Kumar Singh · 2024 · Biocell
  68. Molecular modeling studies of novel naphthyridine and isoquinoline derivatives as CDK8 inhibitors
    Qunlin Li, Kairui Feng, Jianxin Liu, Yujie Ren · 2020 · Journal of Biomolecular Structure and Dynamics
  69. Discovery of 12O—A Novel Oral Multi-Kinase Inhibitor for the Treatment of Solid Tumor
    Yan Liang Fan, Zhi liang Huang, Xiaoshuang Wang, Yakun Ma, Yongtao Li, Shengyong Yang, Yi Shi · 2020 · Molecules
  70. Functionally active cyclin-dependent kinase 9 is essential for porcine reproductive and respiratory syndrome virus subgenomic RNA synthesis
    Meng-Di Wang, Le Yang, Jie-Jie Meng, Jiajia Pan, Chao Zhang, Bo Wan, Yu Sun, Jiang Wang, Bei‐Bei Chu, Gaiping Zhang · 2021 · Molecular Immunology
  71. Expression of CDK9 in endometrial cancer tissues and its effect on the proliferation of HEC-1B
    Wen Jin Yang, Shaoyan Liu, Qiuping Luo, Xuexian Tan · 2021 · Open Life Sciences
  72. Development of CDK2 and CDK5 Dual Degrader TMX‐2172
    Mingxing Teng, Jie Jiang, Zhixiang He, Nicholas P. Kwiatkowski, Katherine A. Donovan, Caitlin E. Mills, Chiara Victor, John M. Hatcher, Eric S. Fischer, Peter Karl Sorger et al. · 2020 · Angewandte Chemie
  73. Clinical CDK2 Inhibitors: Trends to Selectivity and Efficacy
    Polina V. Rusina, Alexey A. Lisov, Alexandra A. Denisova, Erik R. Gandalipov, Fedor N. Novikov, Alexander Albertovich Shtil · 2022 · Recent Patents on Anti-Cancer Drug Discovery
  74. RETRACTED: CDK14 expression is elevated in patients with non-small cell lung cancer and correlated with poor prognosis
    Yong Yang, Guangda Yuan, Hongya Xie, Tengteng Wei, Donglin Zhu, Yimeng Zhu, Shi-Ying Zheng · 2021 · Journal of International Medical Research · Retracted
  75. Promising Cytotoxic butenolides from the Soybean endophytic fungus Aspergillus terreus: a combined molecular docking and in-vitro studies
    Seham S. El‐Hawary, Abeer Sayed Moawad, Hebatallah S. Bahr, Eman Zekry Attia, Mo'men Hamed El-Katatny, Muhamad Mustafa, Ahmed Ali Al-Karmalawy, Mostafa Ezzat Rateb, Jianye Zhang, Usama Ramadan Abdelmohsen et al. · 2023 · Journal of Applied Microbiology
  76. Design and synthesis of CDK9/EZH2 dual-target inhibitors to achieve synergistic antitumor effects
    Lina Tian, Jian Xiao, Yanping Zeng, Yangsha Li, Aihuan Wei, Qianqian Shen, Yixue Han, Yi Chen, Youhong Hu · 2025 · European Journal of Medicinal Chemistry
  77. Novel Small Molecule Inhibitors of Cyclin-dependent Kinases as Anticancer Agents
    Nitin Srivastava, Anil Kumar Saxena · 2025 · Current Medicinal Chemistry
  78. Discovery of novel CDK2 inhibitors using multistage virtual screening and in vitro melanoma cell lines
    Lihong Yang, Mukuo Wang, Beibei Li, Shangqin Xu, Jianping Lin · 2023 · The FASEB Journal
  79. CDK-11-Cyclin L is required for gametogenesis and fertility in C. elegans
    Christopher W. Williams, Jyoti Iyer, Yan Liu, Kevin F. O’Connell · 2018 · Developmental Biology
  80. Converse Smith-Martin cell cycle kinetics by transformed B lymphocytes
    Kim Pham, Andrey Kan, Lachlan W. Whitehead, Robert J. Hennessy, Kelly L. Rogers, Philip D. Hodgkin · 2018 · Cell Cycle
  81. Anti-cancer Dynamics of Natural Phytochemical Inhibitors of Cyclin-Dependent Kinases
    Shyam N. Sundar, Gary L. Firestone · 2020 · Springer eBooks
  82. Establishment and Characterization of a Novel Dedifferentiated Chondrosarcoma Cell Line DDCS2
    Xiaoyang Li, Dylan C. Dean, Al Ferreira, Scott D. Nelson, Francis John Hornicek, Shengji Yu, Zhenfeng Duan · 2021 · Cancer Control
  83. A molecular landscape of quiescence and proliferation highlights the role of Pten in mammary gland acinogenesis
    Rebeka Tomasin, Ana Maria Rodrigues, Antonio Carlos Manucci, Alexandre Bruni‐Cardoso · 2023 · Journal of Cell Science
  84. DISCOVERY OF PYRAZOLOPYRIDINE DERIVATIVES DUALLY TARGETING INFLAMMATION AND PROLIFERATION IN COLORECTAL CANCER CELL LINES: IN-SILICO DRUG DESIGN APPROACH
    Zahra A. Kassem, Raghida Bou Merhi, Doaa A. E. Issa · 2021 · BAU Journal - Health and Wellbeing
  85. Dose and drug changes in chronic lymphocytic leukemia cell response in�vitro: A comparison of standard therapy regimens with two novel cyclin‑dependent kinase inhibitors
    Małgorzata Kubczak, Aleksandra Szustka, Jerzy Z. Błoński, Tomaš Guck�, Małgorzata Misiewicz, Vladimı́r Kryštof, Pawel J. Robak, Małgorzata Rogalińska · 2019 · Molecular Medicine Reports
  86. Design, synthesis, biological and computational evaluation of novel S/N-glycerolyl and peptide-conjugated [1,2,4]triazolo[1,5-a]pyrimidine derivatives as potent CDK2 inhibitors for anticancer therapy
    Ibrahim M. Nagy, Heba A. El-Sayed, Adel A.‐H. Abdel‐Rahman · 2025 · Bioorganic Chemistry
  87. Discovery and optimization of novel tetrahydrothiazolopyridine-based pyrimidines as highly potent cyclin-dependent kinase 9 (CDK9) inhibitors
    Lin Chen, Zhongkai Zou, Jian Fan Cai, Wenbin Zeng, Yan-ting Yann Zhang, Yimeng Liao, Pei‐Liang Zhao · 2025 · European Journal of Medicinal Chemistry
  88. The role of CDK12 in tumor biology
    Marta Dzimková, Jiřina Procházková, Jaroslav Klát, Jiří Kohoutek · 2020 · Klinicka onkologie
  89. Cyclin-Dependent Kinase Inhibitor BMI-1026 Induces Apoptosis by Downregulating Mcl-1 (L) and c-FLIP (L) and Inactivating p-Akt in Human Renal Carcinoma Cells
    Dong‐Eun Kim, Jinho Lee, Jong Wook Park, Hyunsu Kang, Yu Ri Nam, Taeg Kyu Kwon, Ki‐Suk Kim, Shin Kim · 2021 · International Journal of Molecular Sciences
  90. Looking Under the Lamppost: The Search for New Cancer Targets in the Human Kinome
    Mireia Sueca-Comes, Elena Cristina Rusu, Anna M. Grabowska, David O. Bates · 2022 · Pharmacological Reviews
  91. Cdk4/Cdk6 Dysregulation in Estrogen-Positive Receptor Breast Cancers
    Manzoor Ahmad Mir, Ulfat Jan · 2023 · Springer eBooks
  92. QSAR, Molecular Docking & ADMET Studies of Pyrrolo[2,3-d] Pyrimidine Derivatives as CDK4 Inhibitors for the Treatment of Cancer
    Shital Manoj Patil, Varsha A. Patil, Kalyani Asgonkar, Vrushali Randive, Indrani Mahadik · 2023 · Current Indian Science
  93. Modification of Boc-Protected CAN508 via Acylation and Suzuki-Miyaura Coupling
    Martin Pisár, Eva Schütznerová, Filip Hančík, Igor Popa, Zdeněk Trávnı́ček, Petr Cankař · 2018 · Molecules
  94. Identification of Ligand‐binding Hotspot Residues of CDK4 Using Molecular Docking and Molecular Dynamics Simulation
    Pavithra Kuruchi Balasubramanian, Yeongjoon Lee, Yangmee Kim · 2019 · Bulletin of the Korean Chemical Society
  95. For antigen-specific effector or Foxp3+ regulatory T cell fate, cyclin-dependent kinases hold the trump card
    Srinivasa Reddy Bonam, Jagadeesh Bayry · 2019 · Cellular and Molecular Immunology
  96. Distinct states of nucleolar stress induced by anti-cancer drugs
    Tamara Potapova, Jay R. Unruh, Juliana Conkright-Fincham, Charles A.S. Banks, Laurence A. Florens, David Alan Schneider, Jennifer L. Gerton · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  97. Research progress of dual-targeting CDKs regulators for cancer therapy
    Fei-Xia Yue, Yalan Wang, Rui-Yan, Guoqing Chen, Xiaoting Li, Qing‐Kun Shen · 2025 · Bioorganic Chemistry
  98. Reviving p18INK4c: Harnessing a tumor suppressor for cancer treatment
    Dominika Jerka, Klaudia Bonowicz, Yidong Bai, Russel Joseph Reiter, Agnieszka Żuryń, Maciej Gagat · 2025 · Biochemical and Biophysical Research Communications
  99. Discovery of novel cycloalkyl-fused thiazole-based pyrimidine derivatives as highly potent CDK2 inhibitors with promising antitumor activity
    Wen-Ming Tan, Yu Ming Fu, Junwei Chen, Peng-Cheng Diao, Yukang Lin, Zhong-kai Zou, Xie‐Er Jian, Bei Zhang, Pei‐Liang Zhao · 2025 · Bioorganic Chemistry
  100. Selectivity analysis of CDK2 inhibitors via molecular dynamics of CDK1 and CDK2
    Dmitrii O. Shkil, Anastasia S. Fokina, Dariy T. Asainov, Elena V. Petersen, Andrey A. Ivashchenko, Philipp Y. Maximov · 2026 · Journal of Molecular Graphics and Modelling